Allogeneic Bone Marrow Transplant

Clinical trials that involve a procedure in which the patient receives bone marrow or stem cells from a donor to treat a number of different blood and bone marrow cancers.

If you would like to be considered for a clinical trial you will require a referral from your current treating team. Visit the Joining a Clinical Trial page for referral information. 

For more information on clinical trials, get in contact with our cancer clinical trials enquiry coordinator.

Clinical Trials Enquiry Coordinator

Business hours, Mon to Friday between 9am - 2pm
Email [email protected]
Phone (03) 8559 7456

Open and Recruiting Clinical Trials

A clinical trial to test whether giving a treatment called Vedolizumab is safe and can prevent Intestinal Acute Graft-Versus-Host Disease (GVHD), a condition seen in patients undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)

Cancer type

Haematological cancers that have returned after allogeneic stem cell transplant

Status

Open and recruiting

Phase

Three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to what is available for that cancer type.

Brief summary

Patients who undergo Allo-HSCT using immune cells from a donor are at risk of their immune system rejecting the transplant immune cells (GVHD). This clinical trial will test whether the treatment Vedolizumab can prevent the risk of intestinal GVHD. This clinical trial is ‘blinded’ meaning that half of the participants will receive the active treatment and half will receive a placebo or non-active treatment.  

Who can participate

Patients who:

  • Are receiving Allo-HSCT as treatment for a hematologic malignancy or myeloproliferative disorder

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

A clinical trial to test if the treatment Nivolumab can control cancer that has returned after stem cell transplant

Cancer type

Haematological cancers that have returned after allogeneic stem cell transplant

Status

Open and recruiting

Phase

One: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one is to test the safety of the new treatment and find the best dose to give patients.

Brief summary

Blood cancers may return even after someone has had a stem cell transplant to try and cure the cancer. This clinical trial tests whether the treatment Nivolumab can control the cancer if it has returned.

Who can participate

Patients who:

  • Have had a stem cell transplant for blood cancer and whose disease has returned

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

A clinical trial to test if low dose Lenalidomide after allogeneic stem cell transplantation for patients with high risk acute myeloid leukaemia or myelodysplastic syndromes can prevent the cancer coming back

Cancer type

Post allogeneic stem cell transplantation

Status

Open and recruiting

Phase

One: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one is to test the safety of the new treatment and find the best dose to give patients.

Brief summary

Patients who have had an allogeneic stem cell transplant will be given a small dose of the treatment Lenolidamide to try and prevent their underlying disease from coming back.

Who can participate

Patients who:

  • Have had an allogeneic stem cell transplant for high risk acute myeloid leukaemia or myelodysplastic syndromes

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

A clinical trial to test if giving Cyclophosphamide after transplant can prevent graft versus host disease and if this is better than the current standard treatment

Cancer type

Acute Myeloid Leukaemia (AML), Acute Lymphoblastic Leukaemia (ALL)

Status

Open and recruiting

Phase

One: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one is to test the safety of the new treatment and find the best dose to give patients.

Brief summary

The clinical trial aims to find out if the treatment Cyclophosphamide is better than the current standard of care treatment at preventing graft versus host disease in patients who have just had a bone marrow transplant.

Who can participate

Patients who:

  • Aged 18-70 with AML or ALL which is in remission or MDS with <20% myeloblasts
  • Have a 6/6 matched sibling bone marrow donor

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.